Episode # 203 • 03 Dec 2024
Active Surveillance: A Data-Driven Approach
Recent research is changing how we manage low risk prostate cancer. In this BackTable Urology Podcast episode, Dr. Dan Lin, a urologist at the University of Washington, walks through contemporary diagnosis, surveillance, and management of Grade Group 2 prostate cancer with host Dr. Aditya Bagrodia.
This podcast is supported by:
Timestamps
00:00 - Introduction
02:54 - Active Surveillance and Canary PASS Data
12:02 - Biopsy Considerations
19:44 - Active Surveillance Protocols
26:58 - Patient Concerns and Risk Reduction
30:52 - Transitioning Off Surveillance
33:39 - Grade Group 2: Treatment vs. Monitoring
46:24 - Surgical Considerations and Node Dissection
49:25 - Future Directions
Resources
You may also like
More about this episode
The doctors delve into real-world implementation of active surveillance, alongside the use of advanced diagnostics, biopsy methods, and personalized care plans. The conversation highlights the Canary Prostate Active Surveillance Study (PASS) and the prognostic role of biomarkers and genomic testing. Dr. Lin and Dr. Bagrodia also discuss how lifestyle factors such as diet impact cancer progression and how patients can be empowered to manage their disease. Strategies for transitioning patients off surveillance are highlighted. Finally, the two experts discuss insights from recent clinical trials like PIVOT, PROTECT, and SPCG and how they’re impacting prostate cancer management.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.